IBM is in the pipeline. Obviously they have deep pockets.
-
-
They're also being helped out by NHGRI grants, although I'm sure that money doesn't go all that far in developing a new technology and instrument to run it:Originally posted by NextGenSeq View Post
"The firm is one of several companies or researchers that have been awarded at least $5.7 million from the National Human Genome Research Institute this year to support their efforts in developing technologies for sequencing a human genome at low cost."
http://www.genomeweb.com//node/92521...1&v=6b1f3d4880 -
3rd article, guess they were stealth for quite a while. Competition is good. Hope they give PacBio a run for the money (thanks forum sponsors!)
Comment
-
The more skeptical amongst you might have noticed that this press release (containing few/no details beyond previous, very old announcements) came out at a similar time to the announcement of the Justice department's anti-trust probe into IBM...Last edited by 454newbie; 03-08-2011, 10:28 AM.Comment
-
NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...Today, 06:46 AM -
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM
Comment